Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
+$278M |
| 2 |
Exxon Mobil
XOM
|
+$270M |
| 3 |
Verizon
VZ
|
+$141M |
| 4 |
Yum China
YUMC
|
+$135M |
| 5 |
Chevron
CVX
|
+$122M |
Top Sells
Sector Composition
| 1 | Financials | 17.74% |
| 2 | Technology | 15.29% |
| 3 | Industrials | 12.37% |
| 4 | Healthcare | 11.81% |
| 5 | Consumer Discretionary | 9.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTN
3301
DELISTED
Palatin Technologies
PTN
| $135K | ﹤0.01% |
+22,881
| New | +$135K |
|
3302
Globalstar
GSAT
$4.68B
| $133K | ﹤0.01% |
5,563
+950
| +21% | +$22.7K |
|
3303
Vor Biopharma
VOR
$255M
| $131K | ﹤0.01% |
+32,945
| New | +$131K |
|
|
SRNE
3304
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $129K | ﹤0.01% |
82,204
| – | – |
|
3305
Savara
SVRA
$660M
| $126K | ﹤0.01% |
81,408
-14,786
| -15% | -$22.9K |
|
3306
Precision BioSciences
DTIL
$60M
| $125K | ﹤0.01% |
3,190
-2,686
| -46% | -$105K |
|
|
KC
3307
Kingsoft Cloud Holdings
KC
$4.42B
| $123K | ﹤0.01% |
61,902
| – | – |
|
|
PVLA
3308
Palvella Therapeutics, Inc. Common Stock
PVLA
$627M
| $123K | ﹤0.01% |
1,333
-435
| -25% | -$40.1K |
|
3309
Werewolf Therapeutics
HOWL
$62.6M
| $117K | ﹤0.01% |
+25,996
| New | +$117K |
|
3310
Oxbridge Re Holdings
OXBR
$17.1M
| $117K | ﹤0.01% |
54,753
| – | – |
|
3311
SelectQuote
SLQT
$351M
| $117K | ﹤0.01% |
161,127
+19,929
| +14% | +$14.5K |
|
3312
Sono-Tek
SOTK
$62.8M
| $117K | ﹤0.01% |
16,725
+4,386
| +36% | +$30.7K |
|
3313
Harte-Hanks
HHS
$27.2M
| $115K | ﹤0.01% |
+10,348
| New | +$115K |
|
3314
Sypris Solutions
SYPR
$48.1M
| $115K | ﹤0.01% |
61,481
+304
| +0.5% | +$569 |
|
3315
Aveanna Healthcare
AVAH
$1.73B
| $114K | ﹤0.01% |
75,899
-38,360
| -34% | -$57.6K |
|
|
OTIC
3316
DELISTED
Otonomy, Inc.
OTIC
| $112K | ﹤0.01% |
381,902
-507,377
| -57% | -$149K |
|
3317
US Gold Corp
USAU
$180M
| $109K | ﹤0.01% |
29,083
-1,810
| -6% | -$6.78K |
|
|
ATON
3318
AlphaTON Capital Corp. Common Stock
ATON
$13.7M
| $107K | ﹤0.01% |
+784
| New | +$107K |
|
|
IMMP
3319
Immutep
IMMP
$235M
| $106K | ﹤0.01% |
68,386
+10,551
| +18% | +$16.4K |
|
3320
Nortech Systems
NSYS
$25.9M
| $106K | ﹤0.01% |
+10,056
| New | +$106K |
|
3321
Taylor Devices
TAYD
$147M
| $105K | ﹤0.01% |
+10,297
| New | +$105K |
|
3322
Anixa Biosciences
ANIX
$96M
| $104K | ﹤0.01% |
+21,177
| New | +$104K |
|
3323
Abeona Therapeutics
ABEO
$350M
| $103K | ﹤0.01% |
+33,983
| New | +$103K |
|
3324
Biomerica
BMRA
$8.19M
| $102K | ﹤0.01% |
3,259
| – | – |
|
3325
Cineverse
CNVS
$63.1M
| $102K | ﹤0.01% |
12,928
| – | – |
|